PRIME MEDICINE INC (PRME:NASDAQ)
$3.43 -0.08 (-2.2792%)
Analysed PRIME MEDICINE INC (PRME:NASDAQ) News Sources
Prime Medicine (PRME) Focuses on Liver Franchise With $191.4M Cash Runway
08-03-2026
yahoo.com
Prime Medicine, Inc. (PRME) Reports Q4 Loss, Misses Revenue Estimates
03-03-2026
yahoo.com
Prime Medicine Reports Full Year 2025 Financial Results and Provides Business Updates
03-03-2026
yahoo.com
Prime Medicine to Participate in Upcoming Investor Conferences
25-02-2026
yahoo.com
Jacob Funds Bets on Prime Medicine (PRME), a Next-Generation Gene Therapy Company
18-02-2026
yahoo.com
Vanda Pharmaceuticals (VNDA) Reports Q4 Loss, Lags Revenue Estimates
11-02-2026
yahoo.com
Favourable Signals For Prime Medicine: Numerous Insiders Acquired Stock
27-01-2026
yahoo.com
Prime Medicine to Present at 44th Annual J.P. Morgan Healthcare Conference
07-01-2026
yahoo.com
LifeSci Capital Initiates Prime Medicine (PRME), Highlights One-and-Done Potential in Liver and Lung Diseases
31-12-2025
yahoo.com
Prime Medicine, Inc. (PRME) Announces NEJM Publication Of PM359 Data
31-12-2025
yahoo.com
What is the current price of PRIME MEDICINE INC (PRME:NASDAQ)?
The current price of PRIME MEDICINE INC (PRME:NASDAQ) is $3.43.
PRIME MEDICINE INC (PRME:NASDAQ) absolute price change since previous trading day?
The absolute price change of PRIME MEDICINE INC (PRME:NASDAQ) since the previous trading day is $-0.08.
PRIME MEDICINE INC (PRME:NASDAQ) percentage price change since previous trading day?
The percentage price change of PRIME MEDICINE INC (PRME:NASDAQ) since the previous trading day is -2.2792%.
What is the most recent average sentiment score for PRIME MEDICINE INC (PRME:NASDAQ)?
The most recent average sentiment score for PRIME MEDICINE INC (PRME:NASDAQ) is 71 out of 100.
What is the most recent average sentiment for PRIME MEDICINE INC (PRME:NASDAQ)?
The most recent sentiment for PRIME MEDICINE INC (PRME:NASDAQ) is .
SEC-8K** Filing Available For PRIME MEDICINE INC (PRME:NASDAQ)
** material developments that could impact a company's financial condition or stock price.
Author: MattELab
MattELab is the founder and lead developer of SentientMerchant. With a Computer Science and Quantitative Finance background from a T10 university, he brings over 6 years of expertise in NLP, programmatic SEO, and full-stack development to build highly scalable AI and FinTech solutions.